1204405-68-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Boc-2,6-diazabicyclo[3.2.0]heptane is used as a reagent for the preparation of pyrimidine derivatives, which are crucial in the development of KRas G12C inhibitors. These inhibitors are designed to target and treat KRas-mediated diseases, such as certain types of cancer, by specifically inhibiting the mutated KRas G12C protein.
The compound's utility in the synthesis of pyrimidine derivatives highlights its importance in the development of novel therapeutic agents for the treatment of KRas-mediated diseases, making it a valuable asset in the pharmaceutical industry.

Upstream product

• 309962-75-2 rac-tert-butyl (1R,5R)-7-benzyl-4,7-diazabicyclo[3.2.0]heptane-4-carboxylate 
• 1820583-17-2 (7aS)-3-phenyltetrahydro-3H,5H-pyrrolo[1,2-c]oxazol-5-one 
• 121686-87-1 (2R,3S)-N-benzyl-3-hydroxy-2-hydroxymethylpyrrolidine 
• 156129-72-5 (2R,3S)-tert-butyl 3-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 309962-74-1 tert-butyl (2R,3S)-3-((methylsulfonyl)oxy)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate 
• 187039-57-2 (2S,3S)-1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid 
• 17342-08-4 (S)-Pyroglutaminol 

Downstream Products

• 309962-75-2 rac-tert-butyl (1R,5R)-7-benzyl-4,7-diazabicyclo[3.2.0]heptane-4-carboxylate 
• 370880-27-6 2,6-diazabicylo[3.2.0]heptane-2-carboxylic acid tert-butyl ester 
• 1408075-03-5 C₁₀H₁₈N₂O₂ 
• 1408075-03-5 tert-butyl (1S,5S)-2,6-diazabicyclo[3.2.0]heptane-6-carboxylate 

Relevant academic research and scientific papers

QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Diazabicyclic central nervous system active agents

Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.